127 related articles for article (PubMed ID: 22726592)
21. Genotyping of Circulating Free DNA Enables Monitoring of Tumor Dynamics in Synovial Sarcomas.
Eisenhardt AE; Brugger Z; Lausch U; Kiefer J; Zeller J; Runkel A; Schmid A; Bronsert P; Wehrle J; Leithner A; Liegl-Atzwanger B; Giunta RE; Eisenhardt SU; Braig D
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565213
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy and Biomarkers in Sarcoma.
Dajsakdipon T; Siripoon T; Ngamphaiboon N; Ativitavas T; Dejthevaporn T
Curr Treat Options Oncol; 2022 Mar; 23(3):415-438. PubMed ID: 35262852
[TBL] [Abstract][Full Text] [Related]
23. What's next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination.
Redwood AJ; Dick IM; Creaney J; Robinson BWS
Oncoimmunology; 2022; 11(1):2038403. PubMed ID: 35186441
[TBL] [Abstract][Full Text] [Related]
24. Identification of Tumor Antigens and Immune Subtypes for the Development of mRNA Vaccines and Individualized Immunotherapy in Soft Tissue Sarcoma.
Wu C; Duan Y; Gong S; Osterhoff G; Kallendrusch S; Schopow N
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053609
[TBL] [Abstract][Full Text] [Related]
25. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.
Lanzi C; Favini E; Dal Bo L; Tortoreto M; Arrighetti N; Zaffaroni N; Cassinelli G
J Exp Clin Cancer Res; 2021 Dec; 40(1):381. PubMed ID: 34857011
[TBL] [Abstract][Full Text] [Related]
27. Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?
van Oost S; Meijer DM; Kuijjer ML; Bovée JVMG; de Miranda NFCC
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440251
[TBL] [Abstract][Full Text] [Related]
28. The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.
Hildebrand KM; Singla AK; McNeil R; Marritt KL; Hildebrand KN; Zemp F; Rajwani J; Itani D; Bose P; Mahoney DJ; Jirik FR; Monument MJ
PLoS One; 2021; 16(7):e0253864. PubMed ID: 34242269
[TBL] [Abstract][Full Text] [Related]
29. Targeting cancer testis antigens in synovial sarcoma.
Mitchell G; Pollack SM; Wagner MJ
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083416
[TBL] [Abstract][Full Text] [Related]
30. Is immunotherapy in the future of therapeutic management of sarcomas?
Clemente O; Ottaiano A; Di Lorenzo G; Bracigliano A; Lamia S; Cannella L; Pizzolorusso A; Di Marzo M; Santorsola M; De Chiara A; Fazioli F; Tafuto S
J Transl Med; 2021 Apr; 19(1):173. PubMed ID: 33902630
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for sarcomas: new frontiers and unveiled opportunities.
Birdi HK; Jirovec A; Cortés-Kaplan S; Werier J; Nessim C; Diallo JS; Ardolino M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526607
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapeutic strategies for sarcoma: current perspectives.
Li X; Wang G; Cai Z; Sun W
Am J Transl Res; 2020; 12(12):7693-7701. PubMed ID: 33437354
[TBL] [Abstract][Full Text] [Related]
33. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.
Somaiah N; Chawla SP; Block MS; Morris JC; Do K; Kim JW; Druta M; Sankhala KK; Hwu P; Jones RL; Gnjatic S; Kim-Schulze S; Tuballes K; Yishak M; Lu H; Yakovich A; Ter Meulen J; Chen M; Kenney RT; Bohac C; Pollack SM
Oncoimmunology; 2020 Nov; 9(1):1847846. PubMed ID: 33312760
[TBL] [Abstract][Full Text] [Related]
34. Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?
Chew HY; Chan V; Simpson F; Dolcetti R
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207697
[TBL] [Abstract][Full Text] [Related]
35. IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives.
Lapenta C; Gabriele L; Santini SM
Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33086492
[TBL] [Abstract][Full Text] [Related]
36. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.
Leko V; Rosenberg SA
Cancer Cell; 2020 Oct; 38(4):454-472. PubMed ID: 32822573
[TBL] [Abstract][Full Text] [Related]
37. Allogenic γδ T cell and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma.
Wang Y; Zhu J; Yu W; Wang J; Xia K; Liang C; Tao H
J Bone Oncol; 2020 Apr; 21():100214. PubMed ID: 32368439
[TBL] [Abstract][Full Text] [Related]
38. The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures.
Chen L; Oke T; Siegel N; Cojocaru G; Tam AJ; Blosser RL; Swailes J; Ligon JA; Lebid A; Morris C; Levin A; Rhee DS; Johnston FM; Greer JB; Meyer CF; Ladle BH; Thompson ED; Montgomery EA; Choi W; McConkey DJ; Anders RA; Pardoll DM; Llosa NJ
Clin Cancer Res; 2020 Aug; 26(15):4018-4030. PubMed ID: 32332015
[TBL] [Abstract][Full Text] [Related]
39. Molecular targets and novel therapeutic avenues in soft-tissue sarcoma.
Elkrief A; Alcindor T
Curr Oncol; 2020 Feb; 27(Suppl 1):34-40. PubMed ID: 32174756
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in soft-tissue sarcoma.
Ayodele O; Razak ARA
Curr Oncol; 2020 Feb; 27(Suppl 1):17-23. PubMed ID: 32174754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
